Click to download the PDF to view the full issue Although the company’s long-time best seller Plavix fell off patent in 2012, a number of Bristol-Myers Squibb’s newer compounds – both already on the market and in the pipeline – are showing signs of future potential. For Bristol-Myers Squibb, 2012 was a year of strategic […]

Click to download the PDF to view the full issue With revenue of more than $20 billion, the largest generics portfolio globally, the world’s leading multiple sclerosis product, and a growing presence in oncology, Teva has earned a place at the big kids’ table in the pharma world. The Teva train just kept rolling down […]

Click to download the PDF to view the full issue Battered by the expiration of exclusivity of blockbuster products, Sanofi is driven to grow other areas of its business. The patent cliff continued to take its toll on Sanofi during 2012 and first-half 2013. But executives believe that the worst is probably over and they […]

Click to download the PDF to view the full issue Roche once again enjoyed growth in 2012 despite market difficulties, and the company continues its winning strategy of developing drugs for unmet needs and companion diagnostics. Despite increasing cost pressures in many markets, 2012 was a positive year for Roche, in which the company posted […]

Click to download the PDF to view the full issue As Pfizer continues to be weighed down by Lipitor’s patent expiration, the company has sold off its animal health business and is moving to internally split its commercial operations into three business segments. At Pfizer, there is a new slogan and a new attitude. As […]

Click to download the PDF to view the full issue Med Ad News: What do you feel are the major strategic and marketplace challenges today for a company such as Novo Nordisk, and how is the company meeting those challenges? LS: One of the challenges is one we share with all of the pharmaceutical companies, […]